Why DualityBio’s China filing for trastuzumab pamirtecan matters in the HER2 breast cancer ADC race
DualityBio’s trastuzumab pamirtecan has entered China review for HER2-positive breast cancer. Read what this filing could change next.
Can zemprocitinib help Lynk Pharmaceuticals break into China’s crowded atopic dermatitis market?
Lynk Pharmaceuticals won NMPA acceptance for zemprocitinib in atopic dermatitis. Read what this filing changes, and what risks still remain.
Can Ascletis’ denifanstat reshape acne treatment by targeting fatty acid synthesis?
Ascletis’ acne drug denifanstat advances with NDA acceptance in China. Explore how FASN targeting could disrupt acne care and redefine systemic treatments.